Drug Type CAR-NK |
Synonyms KN 5501, KN-5501, KN5501 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Antisynthetase Syndrome | Phase 1 | - | 20 Oct 2024 | |
Antisynthetase Syndrome | Phase 1 | - | 20 Oct 2024 | |
Rheumatoid Arthritis | Phase 1 | - | 20 Oct 2024 | |
Rheumatoid Arthritis | Phase 1 | - | 20 Oct 2024 | |
Alloimmune thrombocytopenia | Phase 1 | - | 30 Aug 2024 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | - | 30 Aug 2024 | |
Autoimmune Diseases | Phase 1 | CN | 27 Jun 2024 | |
Immune-mediated renal disorder | Phase 1 | CN | 21 Jun 2024 |
ACR2024 Manual | Not Applicable | 20 | svsxivtsen(hmsabrmjnx) = Reconstitution of B cells was observed in 2 to 3 months post CAR-NK cells therapy. oqjgwkwgce (nxeoqrjjif ) View more | Positive | 24 Oct 2024 |